Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

565
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
565
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.7K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.7K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

555
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
555
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

959
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
959
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
837

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Inflammatory bowel disease in the aging population.

Inflammatory bowel diseases·2026
Same author

Multi-task artificial intelligence annotation of echocardiographic images: a retrospective multi-cohort study.

medRxiv : the preprint server for health sciences·2026
Same author

Dual-targeted therapy with risankizumab and upadacitinib in medically complex Crohn's disease.

Crohn's & colitis 360·2026
Same author

Impact of Upadacitinib on Cardiovascular Events and Lipid Values in Older Inflammatory Bowel Disease Patients with Baseline Cardiovascular Risk.

The American journal of gastroenterology·2026
Same author

Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.

Digestive diseases and sciences·2026
Same author

Primer: Understanding Medicare for Advanced Therapies for Inflammatory Bowel Disease.

The American journal of gastroenterology·2026

関連する実験動画

Updated: Feb 24, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.7K

活性性潰瘍性大腸炎に対するカルキュミン-QingDaiの組み合わせ:費用対効果の分析

Henit Yanai1, David Choi2, Shomron Ben-Horin3

  • 1Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
|February 22, 2026
PubMed
まとめ

カルキュミンとクィンダイ (CurQD) は,先端療法と比較して,潰瘍性大腸炎 (UC) の費用対効果の高い治療法を提供します. このニュートラセウティカルには大きな利点があり,UCが活発な患者にとって貴重な選択肢です.

キーワード:
費用対効果 費用対効果炎症性腸疾患とはトリートメント トリートメント潰瘍性大腸炎について

さらに関連する動画

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

関連する実験動画

Last Updated: Feb 24, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.7K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.3K

科学分野:

  • 胃腸内科 胃腸内科
  • 薬学経済学 薬学経済学
  • 統合医療とは一体化医療です.

背景:

  • アクティブな潰瘍性大腸炎 (UC) の治療には,しばしば高度な治療法が含まれます.
  • カルキュミンとキングダイ (CurQD) は,ハーブ化合物であり,UC管理に有望であることが示されています.
  • UC治療におけるCurQDの費用対効果に関する事前の分析は存在しない.

研究 の 目的:

  • CurQDの費用対効果を,中等から重度のUCの現在の高度な治療法と比較して評価する.
  • 先進治療の先天的および経験豊富なUC患者コホートの両方の費用対効果を分析するために.

主な方法:

  • マルコフモデルで54週間にわたってUC患者の進行をシミュレートした.
  • ランダム化比較試験と現実世界の研究から合成された有効性データ.
  • 米国の平均卸売価格に基づくコストデータ; $50,000/QALYの値を使用した.

主要な成果:

  • CurQDは,高度な治療法に対して$200,000/QALYを超えるインクリメンタル費用対効果比 (ICER) を実証しました.
  • 品質調整寿命年 (QALY) の差は, -0.1から0.07.までの範囲で,わずかなものでした.
  • 感受性分析は,調査結果の信頼性を確認した.

結論:

  • CurQDは,UCの先進的な治療法に対して,非常に費用対効果の高い代替手段を提示しています.
  • CurQDのコスト削減と実証された有効性は,説得力のある利点を提供します.
  • これには,活性UCの抗TNFバイオシミラーに対する費用対効果が含まれます.